How I treat influenza in patients with hematologic malignancies

Blood

Volumn 115, Issue 7, 2010, Pages 1331-1342

  Casper, Corey ^a,b,c,d   Englund, Janet ^e   Boeckh, Michael ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; ZANAMIVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CAREGIVER; FAMILY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INFLUENZA VIRUS C; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; PARENT; PRIORITY JOURNAL; PROPHYLAXIS; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VIRUS STRAIN; BLOOD DISEASE; COMORBIDITY; EPIDEMIC; REVIEW;

ANTIVIRAL AGENTS; COMORBIDITY; DISEASE OUTBREAKS; HEMATOLOGIC NEOPLASMS; HUMANS; INFECTION CONTROL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN;

EID: 77949894046     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-255455     Document Type: Article

References (95)

1. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880-1887.
2. Swine influenzaA(H1N1) infection in two children - Southern California, March-April 2009.MMWRMorb Mortal Wkly Rep. 2009;58(15):400-402.
3. Centers for Disease Control and Prevention. 2009 H1N1 Flu: International Situation Update. http://www.cdc.gov/h1n1flu/updates/international.Accessed October 17, 2009.
4. US Centers for Disease Control and Prevention. Percentage of Visits for Influenza-like-Illness Reported by Sentinel Providers 2009-2010. http://www.cdc.gov/flu/weekly/weeklyarchives2009-2010/data/senAllregt46.htm. Accessed January 21, 2010.
5. Morens DM, Taubenberger JK, Fauci AS. The persistent legacy of the 1918 influenza virus. N Engl J Med. 2009;361(3):225-229.
6. US Centers for Disease Control and Prevention. 2009 H1N1 Early Outbreak and Disease Characteristics. http://www.cdc.gov/H1N1FLU/surveillanceqa.htm. Accessed January 21, 2010.
7. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361(20): 1945-1952.
8. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361(25):2405-2413.
9. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009;361(25):2414-2423.
10. Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill. 2009; 14(33):19309.
11. Whimbey E, Elting LS, Couch RB, et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant. 1994;13(4):437-440.
12. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer. 1995;3(3):198-202.
13. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis. 1997;24(6):1095-1099.
14. Weinstock DM, Eagan J, Malak SA, et al. Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol. 2000;21(11):730-732.
15. Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110(5): 1681-1688.
16. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004; 39(9):1300-1306.
17. Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007;28(2):222-242.
18. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006;85(5):278-287.
19. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant. 2001;7(suppl):5S-7S.
20. Shah J, VigilL K, Adachi J, Granwehr B, Raad I, Chemaly R. Influenza virus infections in pediatric cancer patients - emphasis on preemptive therapy [abstract]. Presented at the Annual Meeting of the Infectious Disease Society of America, Philadelphia, PA, October 31, 2009. Abstract 1098.
21. Campbell A, Chien J, Kuypers J, et al. Respiratory virus pneumonia after hematopoietic cell transplantation: viral load in bronchoalveolar lavage and RNA detection in serum as possible predictors of outcome. J Infect Dis. In press.
22. Munster VJ, de Wit E, van den Brand JM, et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science. 2009;325(5939):481-483.
23. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203-1207.
24. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143(4):455-467.
25. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007;44(7):964-967.
26. Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant. 2003;31(8):695-700.
27. Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193(12):1619-1625.
28. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302(17):1872-1879.
29. Lapinsky SE. H1N1 novel influenza A in pregnant and immunocompromised patients. Crit Care Med. November 23, 2009.
30. Redelman-Sidi G, Kamboj M, Huang C-K, et al. Pandemic H1N1 Influenza Infection in Cancer Patients. Presented at the Annual Meeting of the Infectious Disease Society of America, Philadelphia, PA, November 1, 2009. Abstract LB-51.
31. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605-2615.
32. Ginocchio CC, Zhang F, Manji R, et al. Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol. 2009;45(3):191-195.
33. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A (H1N1) virus. JAMA. 2009;301(10):1042-1046.
34. Kaiser L, Briones MS, Hayden FG. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol. 1999;14(3):191-197.
35. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493-504.
36. US Centers for Disease Control and Prevention. Accessed --.
37. Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med. 2009; 361(17):1713-1714.
38. Shima T, Yoshimoto G, Nonami A, et al. Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient. Int J Hematol. 2008;88(3):336-340.
39. Chakrabarti S, Collingham KE, Holder K, Fegan CD, Osman H, Milligan DW. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. 2001;28(8):759-763.
40. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997;19(9):905-908.
41. Machado CM. Influenza infections after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;41(2):273-274.
42. Johny AA, Clark A, Price N, Carrington D, Oakhill A, Marks DI. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 29(2):113-115.
43. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11(2):100-105.
44. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial: US Oral Neuraminidase Study Group. JAMA. 2000;283(8):1016- 1024.
45. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial: Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355(9218):1845-1850.
46. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother. 2007;51(4):1414-1424.
47. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis. 2009;199(10): 1435-1441.
48. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003;8(3):183-190.
49. Nguyen JT, Hoopes JD, Smee DF, et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother. 2009;53(10):4115-4126.
50. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother. 2009; 53(5):2120-2128.
51. Smee DF, Hurst BL, Wong MH, et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza a virus infections in mice. Antimicrob Agents Chemother. 2010;54(1):126-133.
52. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis. 2009;48(9):1254- 1256.
53. Nguyen J, Hoopes J, Le M, Prichard M, Went G. InVitro Activity of Triple Combination Therapy against Drug-Resistant InfluenzaViruses. Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2009.
54. Gordon L, Johnson P, PermezelL M, et al. Association between Severe Swine-origin Influenza A Virus (S-OIV) Infection and Immunoglobulin G2 Subclass Deficiency Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; 2009.
55. US Centers for Disease Control and Prevention. Emergency Use Authorization of Peramivir IV Fact Sheet For Health Care Providers. http://www.cdc.gov/h1n1flu/eua/Final%20HCP% 20Fact%20sheet%20Peramivir%20IV-CDC. pdf.November 19, 2009. Accessed January 21, 2010.
56. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358(3): 261-273.
57. Quispe-Laime AM, Bracco JD, Barberio PA, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med. 2010;36(1):33-41.
58. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective: preface. Bone Marrow Transplant. 2009;44(8):453-455.
59. Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009; 94(8):1101-1108.
60. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther. 2007;12(4):501-508.
61. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(32):893-896.
62. Koyama K, Takahashi M, Oitate M, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009;53(11): 4845-4851.
63. Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: novel broadspectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82(3):95-102.
64. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem. 2009; 284(43):29798-29808.
65. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48(suppl 1):S3-S13.
66. Triana-Baltzer GB, Gubareva LV, Klimov AI, et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009;4(11):e7838.
67. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broadspectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006;50(4):1470-1479.
68. Chan RW, Chan MC, Wong AC, et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother. 2009;53(9):3935-3941.
69. Grayson ML, Melvani S, Druce J, et al. Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis. 2009;48(3):285-291.
70. Cowling BJ, Chan KH, Fang VJ, et al. Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. Ann Intern Med. 2009;151(7):437-446.
71. Jefferson T, Del Mar C, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ. 2009;339:b3675.
72. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (http://www. cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf). Accessed January 21, 2010.
73. Centers for Disease Control and Prevention. Interim Guidance on Infection Control Measures for 2009 H1N1 Influenza in Healthcare Settings, Including Protection of Healthcare Personnel (http://www.cdc.gov/h1n1flu/guidelines- infection-control.htm). Accessed January 21, 2010.
74. World Health Organization. Infection prevention and control in health care for confirmed or suspected cases of pandemic (H1N1) 2009 and influenza-like illnesses (http://www.who.int/csr/resources/publications/swineflu/ swineinfinfcont/en/index.html). Accessed January 21, 2010.
75. Public Health Agency of Canada. Guidance: Infection prevention and control measures for Health Care Workers in Acute Care Facilities (http://www.phac-aspc.gc.ca/alert-alerte/h1n1/hpps/ig-acf-ld-esa-eng.php). Accessed October 18, 2009.
76. Institute of Medicine. Respiratory Protection for Healthcare Workers in the Workplace Against Novel H1N1 Influenza A (http://www.iom.edu/en/Reports/ 2009/RespProtH1N1.aspx). Accessed October 18, 2009.
77. www.sheaonline.org/. . ./FINAL-Joint-SHEA-APIC-IDSA-ACOEM-Position- Statement-High-Risk-HCW.pdf. Accessed January 21, 2010.
78. Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA. 2009;302(17):1865-1871.
79. Ring A, Marx G, Steer C, Harper P. Influenza vaccination and chemotherapy: a shot in the dark? Support Care Cancer. 2002;10(6):462-465.
80. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant. 2008;42(10):637-641.
81. Ortbals DW, Liebhaber H, Presant CA, Van Amburg AL III, Lee JY. Influenza immunization of adult patients with malignant diseases. Ann Intern Med. 1977;87(5):552-557.
82. Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000;82(7):1261-1265.
83. Thomas RE, Jefferson T, Demicheli V, Rivetti D. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev. 2006;3:CD005187.
84. Tilburt JC, Mueller PS, Ottenberg AL, Poland GA, Koenig BA. Facing the challenges of influenza in healthcare settings: the ethical rationale for mandatory seasonal influenza vaccination and its implications for future pandemics. Vaccine. 2008; 26(suppl 4):D27-D30.
85. Ribner BS, Hall C, Steinberg JP, et al. Use of a mandatory declination form in a program for influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol. 2008;29(4):302-308.
86. Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol. 2007;28(6):702-707.
87. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA. 2005;294(21): 2720-2725.
88. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J. 2006;25(7):590-595.
89. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25(10):860-869.
90. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361(13): 1260-1267.
91. King JC Jr, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J. 2001;20(12):1124-1131.
92. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009;58(RR-8):1-52.
93. Witkop CT, Duffy MR, Macias EA, et al. Novel Influenza A (H1N1) Outbreak at the U.S. Air Force Academy Epidemiology and Viral Shedding Duration. Am J Prev Med. October 21, 2009. [Epub ahead of print]
94. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis. 2007; 45(2):187-193.
95. Ison M, Szakaly P, Shapira M, Kriván G, Nist A, Dutkowski R. Oseltamivir prophylaxis significantly reduces the incidence of seasonal influenza infection in immunocompromized patients. XI International Symposium on Respiratory Viral Infections. Bangkok, Thailand; 2009.